Naslov
Continuous infusion of remimazolam for intraoperative sedation as a safe and effective option: a prospective clinical study

Autori
Kustura, Antonia ; Lijović, Lada ; Bolanča, Antonija ; Kovač, Nataša ; Pažur, Iva ; Radočaj, Tomislav

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
European Journal of Anaesthesiology, Volume 40 | e- Supplement 61 | June 2023 / Samama, Charles M. - Hagerstown, NJ : Wolters Kluwer Health, Inc., 2023, 98 / - , 2023, 98-98

Skup
Euroanesthesia 2023

Mjesto i datum
Glasgow, Ujedinjeno Kraljevstvo, 03.06.2023. - 05.06.2023

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
remimazolam ; sedacija ; anestezija ; BIS ; benzodiazepini
(remimazolam ; sedation ; anesthesia ; BIS ; benzodiazepine)

Sažetak
Background and Goal of Study: The purpose of our study was to identify the appropriate dosage of continuous remimazolam that would provide satisfactory sedative and hypnotic ef fects to the patients, i.e., to procure a BIS score of 60 to 80 and/or Richmond sedation scale (RASS) value of -2 or -3. Materials and Methods: 23 patients of ASA status II, III or IV undergoing surgical procedures in spinal anaesthesia were studied. Af ter assessing for adequate quality of spinal block, and at the beginning of the surgical procedure, a bolus dose of remimazolam of 5 mg was applied, and syringe pump was set to deliver remimazolam 1 mg/mL at 15 mL/h, adjusting the rate of infusion to maintain BIS values between 60 and 80. BIS, Richmond sedation scale (RASS) and infusion rate were noted every 5 minutes. Side ef fects (hypotension, bradycardia, hypoxia) were monitored. Results and Discussion: Mean patients’ age was 67.3 ± 13.1 years with male frequency of 56.6%. There were 15 (65.2%) ASA II patients and 8 (34.8%) ASA III patients. When the BIS values were between 60 and 80, the median dose of infused remimazolam was 3.2 mcg/ kg/min (ranging from 1.0 to 5.1 mcg/kg/min ; Q1 2.4, Q3 4.1). Results are graphically represented in Figure 1. Median time from discontinuation of infusion until full recovery of consciousness was 3.5 minutes (ranging from 0 to 8 min ; Q1 1.5, Q3 5.0). Hypotension was recorded in 7 patients, with only 4 cases (17.4%) needing treatment with low doses of ephedrine. No other side ef fects were recorded. Patients reported satisfactory amnestic ef fects (86.9%) af terwards. Conclusion(s): Continuous infusion of remimazolam with median dose of 3.2 mcg/kg/min has provided an ef fective and satisfactory sedative and hypnotic levels for non-healthy individuals, measured by BIS and Richmond sedation scale, with rapid of fset and early recovery.

Izvorni jezik
Engleski

Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA